Related Experiment Video
Updated: Jan 31, 2026

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
Published on: September 11, 2015
Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth
Eisaku Miyauchi1,2, Tatsuo Matsuda1, Kazuma Kiyotani3
1Department of Medicine, The University of Chicago, Chicago, Illinois.
Abstract:
Recent clinical trials of non-small cell lung cancer with immune checkpoint inhibitors revealed that patients with epidermal growth factor receptor (EGFR) mutations had more unfavorable outcomes compared with those with wild-type EGFR. However, the underlying mechanism for the link between EGFR mutations and immune resistance remains unclear. We performed T cell receptor (TCR) repertoire analysis of resected lung adenocarcinoma tissues with and without EGFR mutations to investigate the characteristics of TCR repertoires. We collected a total of 39 paired (normal and tumor) lung tissue samples (20 had EGFR mutations) and conducted TCR repertoire analysis as well as whole-exome sequencing (WES) and transcriptome analysis. The TCR diversity index in EGFR-mutant tumors was significantly higher than that in EGFR-wild-type tumors (median [range] 552 [162-1,135] vs 230 [30-764]; P < .01), suggesting higher T cell clonal expansion in EGFR-wild-type tumors than in EGFR-mutant tumors. In WES, EGFR-mutant tumors showed lower numbers of non-synonymous mutations and predicted neoantigens than EGFR-wild-type tumors (P < .01, P = .03, respectively). The number of non-synonymous mutations revealed a positive correlation with the sum of frequencies of the TCRβ clonotypes of 1% or higher in tumors (r = .52, P = .04). The present study demonstrates significant differences in TCR repertoires and the number of predicted neoantigens between EGFR-mutant and wild-type lung tumors. Our findings provide important information for understanding the molecular mechanism behind EGFR-mutant patients showing unfavorable responses to immune checkpoint inhibitors.
Insights
Patients with EGFR-mutant lung cancer show poorer outcomes with immune checkpoint inhibitors. This study found EGFR mutations are linked to altered T cell receptor repertoires and fewer neoantigens, explaining immune resistance.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Immune checkpoint inhibitors (ICIs) show varied efficacy in non-small cell lung cancer (NSCLC).
- Patients with epidermal growth factor receptor (EGFR) mutations often experience worse outcomes with ICIs.
- The mechanisms underlying EGFR mutation-associated immune resistance are not fully understood.
Purpose of the Study:
- To investigate T cell receptor (TCR) repertoire characteristics in lung adenocarcinoma with and without EGFR mutations.
- To explore the relationship between EGFR mutation status, TCR repertoire, and tumor mutational landscape.
Main Methods:
- Collected 39 paired lung adenocarcinoma tissues (20 with EGFR mutations).
- Performed TCR repertoire analysis, whole-exome sequencing (WES), and transcriptome analysis.
- Analyzed TCR diversity, non-synonymous mutations, and predicted neoantigens.
Main Results:
- EGFR-mutant tumors exhibited significantly higher TCR diversity compared to wild-type tumors, indicating lower T cell clonal expansion.
- EGFR-mutant tumors had fewer non-synonymous mutations and predicted neoantigens than wild-type tumors.
- A positive correlation was observed between non-synonymous mutations and TCRβ clonotype frequencies.
Conclusions:
- Significant differences exist in TCR repertoires and neoantigen load between EGFR-mutant and wild-type lung tumors.
- These findings provide insights into the molecular mechanisms of immune resistance in EGFR-mutant NSCLC.
- Understanding these differences may guide the development of targeted immunotherapies for specific patient subgroups.
More Related Videos
Related Concept Videos
Internal Receptors
Types of Receptors: Cell Surface Receptors
Receptor-mediated Endocytosis
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
G-protein Coupled Receptors
Types of Receptors: Internal Receptors
Similar to membrane-bound receptors, the binding of a ligand to the intracellular receptor of causes a conformational change in the...

